How a claim degrades between the bench and the listing
A badge asserts that something was tested. It does not assert what, when, on whose sample, by what method, or whether the lot on sale is the lot that was tested.
The Ledger
Page 14 of 25 of this archive, newest first.
Page 14
Side effects, cost, supply, target: four reasons with four trajectories
Why the reason for stopping changes what happens afterwards.
New Zealand declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
An interlaboratory comparison nobody had run
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
The United Arab Emirates declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
What TRIUMPH-3 tells us about maintenance, and what it does not
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Singapore caps liraglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Turkey declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
What SURPASS-4 tells us about maintenance, and what it does not
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Nigeria declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
How a claim degrades between the bench and the listing
The Journal does not treat a badge as evidence and states so wherever it reports one.
Six words a verification badge would need to mean anything
What a verification mark would have to carry to be checkable: a date, a lot, a method, a submitter and a link to the report.
Japan caps semaglutide prescribing to 13 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Side effects, cost, supply, target: four reasons with four trajectories
A supply interruption is a discontinuation with no notice, no taper and no plan. That is a distinct clinical situation.
Sending the same vial twice, under two names
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
South Africa caps tirzepatide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Japan declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The supply gap as a clinical event
Why the reason for stopping changes what happens afterwards.
France caps semaglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Three services, one lot, and a spread of two and a half points
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.